<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00496847</url>
  </required_header>
  <id_info>
    <org_study_id>VB023/07</org_study_id>
    <nct_id>NCT00496847</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect</brief_title>
  <official_title>Study on the Efficacy and Safety of PERIOGEN in the Treatment of Periodontal Bone Defect - A Double-blind, Controlled, Randomised,Parallel,Multi-centre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virchow Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virchow Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PERIOGEN, containing rhPDGF and -beta-TCP, promotes gingival healing and corrects periodontal
      defects. This study will test the safety and efficacy of PERIOGEN in the treatment of
      periodontal disease
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sixty eligible patients with periodontal defect will randomly receive either beta-TCP
      implantation (control group) or PERIOGEN implantation, containing beta-TCP and rhPDGF (drug
      group). The specified primary and secondary end points related to efficacy and safety will be
      assessed during 6 months study period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1.Area under curve (AUC) of clinical attachment level (CAL) gain (0-24 weeks) 2.Extent of linear bone growth (LBG) and percentage of bone fill (%BF) at 6 months.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1.Changes in CAL gain, probing depth and gingival recession at 3 and 6 months. 2.Incidence of adverse events.</measure>
    <time_frame>3 and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Intrabony Periodontal Defect</condition>
  <arm_group>
    <arm_group_label>Drug Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PERIOGEN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Beta TCP alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PERIOGEN</intervention_name>
    <description>Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)</description>
    <arm_group_label>Drug Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beta TCP alone</intervention_name>
    <description>Implantation of β-TCP (0.5 g) alone</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Probing depth ≥7 mm at baseline

          2. Presence of ≥4 mm vertical bone defect with at least 1 bony wall after surgical
             debridement.

          3. Adequate keratinized tissue to permit complete tissue coverage of defect.

          4. Radiographic base of defect ≥3 mm coronal to the apex of the tooth.

        Exclusion Criteria:

          1. Failure to maintain adequate oral hygiene (plaque index&gt;2)

          2. Pregnant and lactating women

          3. History of oral cancer or HIV

          4. Periodontal surgery on treatment-targeted tooth within the last year.

          5. Tooth mobility greater than grade II.

          6. Study tooth exhibiting a class III furacation defect

          7. Localized aggressive periodontitis

          8. Radiographic signs of untreated acute infection at the surgical site

          9. Recent history of smoking more than 20 cigarettes/day

         10. Known allergy to E.coli-derived products

         11. Using an investigational therapy within the past 30 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A Jayakumar, MDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sri Sai Dental college of surgery, Vikarabad, RR Dist, AP, India.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sri Sai Dental college of surgery, Vikarabad,</name>
      <address>
        <city>RR Dist</city>
        <state>Andhra pradesh</state>
        <zip>501101</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2007</study_first_submitted>
  <study_first_submitted_qc>July 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2007</study_first_posted>
  <last_update_submitted>December 15, 2014</last_update_submitted>
  <last_update_submitted_qc>December 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rhPDGF,</keyword>
  <keyword>periodontal disease</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

